HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
Jie Mei(Sun Yat-sen University), Junying Xu(Wuxi People's Hospital), Yuan Wan(Binghamton University), Mingfeng Zheng(Wuxi No.2 People's Hospital), Yundi Chen(Binghamton University), Guanyu Jiang(Wuxi No.2 People's Hospital), Feng Liu(Nanjing Medical University), Yongrui Xu(Wuxi People's Hospital), Ruo Chen(Beijing University of Chinese Medicine), Wenjun Mao(Wuxi People's Hospital)
Cited by 35
Related Papers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
The role of lipid metabolic reprogramming in tumor microenvironment
|Theranostics|2023|223
Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment
|Cell Reports|2024|70
Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial
|Signal Transduction and Targeted Therapy|2021|66
Chimeric nanobody-decorated liposomes by self-assembly
|Nature Nanotechnology|2024|65